Medication Use and Quality of Life Among Older People (Pilot)

Quality of Life Clinical Trial

Official title:

Medication Use and Quality of Life Among Older People (Pilot)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04676984
• Other study ID #: ODIN-1 Pilot
• Status: Completed
• Phase: N/A
• Start date: June 1, 2020
• Est. completion date: July 8, 2021

Study information

• Verified date: April 2022
• Source: Odense University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This project will provide new evidence on how to optimize medication use among older people with limited life expectancy. This will be done by testing whether a patient-centered deprescribing intervention, focused on aligning medical treatment with patients' preferences, can improve quality of life among older people with limited life expectancy. This registration concerns the initial pilot study.

Description:

In a pragmatic randomized controlled trial, this project will test whether a comprehensive and patient-centered deprescribing intervention can improve quality of life among older people with limited life expectancy. This registration concerns the initial pilot study. All patients included in the pilot study will receive the intervention (that is, the pilot study will not include randomization). The intervention will comprise a series of consultations between the patient and general practitioner (GP) (at least three) to continuously adjust the patient's medication according to the patient's goals, needs, and preferences, thereby ensuring alignment with the patient's priorities. Thus, the purpose of this intervention is to initiate and facilitate a continued deprescribing process. The process can be summarized in seven steps: During an initial consultation (1: Consultation 0), the GP assesses patient eligibility. If the patient would like to participate, a project nurse subsequently visits the patient at home (2: Home visit) for retrieval of informed consent as well as baseline measurements. During the next consultation (3: Consultation 1), the patient and GP discuss how the patient feels about his/her medical treatment, and the GP provides the patient with written material for the patient to prepare prior to the next consultation. The patients prepares (4: Preparation) by considering and verbalizing his/her goals of care and treatment preferences. Simultaneously, a clinical pharmacist examines the patient's medication list and provides suggestions to the GP on which drugs can be continued and deprescribed, respectively. During the next consultation (5: Consultation 2), the patient and GP discuss the patient's preferences and initiate deprescribing initiatives aligned with the patient's priorities. During a new consultation (6: Consultation 3), the patient and GP follow up on the changes initiated and initiate new deprescribing initiatives if such can be identified. If needed, subsequent consultations (7: Consultation X) are planned until the patient and GP consider the patient's medical treatment optimal.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3
• Est. completion date: July 8, 2021
• Est. primary completion date: April 12, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 80 Years and older

Eligibility

Inclusion criteria:

• Aged =80 years
• Take =8 different medications
• Have a life expectancy of <2 years, estimated via the Surprise Question ("Would you be surprised if this patient died within 1-2 years?") by the general practitioner
• Have a Mini-Mental State Exam (MMSE) score of =15
• Are able to provide informed consent

Exclusion Criteria:

• Not able to communicate
• Does not speak and understand Danish

Related Conditions & MeSH terms

• Quality of Life
• Reduction, Harm

Intervention

Other:
• Consultations
The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.

Locations

Country	Name	City	State
Denmark	Odense University Hospital	Odense	Region Of Southern Denmark

Sponsors (2)

Lead Sponsor	Collaborator
Odense University Hospital	University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HEALTH-RELATED QUALITY OF LIFE	Health-related quality of life will be measured using the Danish version of the SF-12v2 Health Survey.	Baseline
Primary	CHANGE FROM BASELINE HEALTH-RELATED QUALITY OF LIFE AT 3 MONTHS	Health-related quality of life will be measured using the Danish version of the SF-12v2 Health Survey.	3 months
Primary	CHANGE FROM BASELINE HEALTH-RELATED QUALITY OF LIFE AT 6 MONTHS	Health-related quality of life will be measured using the Danish version of the SF-12v2 Health Survey.	6 months
Primary	HEALTH-RELATED QUALITY OF LIFE (DEPRESSION)	Health-related quality of life will be measured using the Danish version of the Depression List.	Baseline
Primary	CHANGE FROM BASELINE HEALTH-RELATED QUALITY OF LIFE (DEPRESSION) AT 3 MONTHS	Health-related quality of life will be measured using the Danish version of the Depression List.	3 months
Primary	CHANGE FROM BASELINE HEALTH-RELATED QUALITY OF LIFE (DEPRESSION) AT 6 MONTHS	Health-related quality of life will be measured using the Danish version of the Depression List.	6 months
Primary	MORTALITY	Mortality will be assessed through the nationwide Danish Central Person Registry.	3 months
Primary	MORTALITY	Mortality will be assessed through the nationwide Danish Central Person Registry.	6 months
Primary	MORTALITY	Mortality will be assessed through the nationwide Danish Central Person Registry.	12 months
Secondary	COGNITIVE FUNCTION	Cognitive function will be measured using the Danish version of the Mini-Mental State Examination-2 (MMSE-2) Standard Form.	Baseline, 3 months and 6 months
Secondary	FUNCTIONAL LEVEL	Functional level will be measured using the Danish version of the Vulnerable Elders Survey 13 (VES-13).	Baseline, 3 months and 6 months
Secondary	HAND-GRIP STRENGTH	Hand-grip strength will be measured using a hand-grip dynamometer.	Baseline, 3 months and 6 months
Secondary	ABILITY TO SIT AND STAND	Ability to sit and stand will be measured via the 30-second stand-sit-test.	Baseline, 3 months and 6 months
Secondary	NUMBER OF MEDICATIONS DISCONTINUED	Number of medications dicontinued will be assessed through the medication lists.	3 months, 6 months and 12 months
Secondary	NUMBER OF MEDICATION CHANGES	Number of medication changes will be assessed through the medication lists.	3 months, 6 months and 12 months
Secondary	HOSPITAL ADMISSIONS	Admissions will be assessed through the nationwide Danish National Patient Register.	3 months, 6 months and 12 months
Secondary	HEALTH CARE COSTS	Health care costs.	3 months, 6 months and 12 months
Secondary	SUCCESS RATE OF THE INTERVENTION	Succes rate of the intervention.	3 months, 6 months and 12 months